Skip to content
Markets News
Stocks1 min read

Bayer Shares Rise on Nubeqa Data in Early Prostate Cancer

Makkler Newsroom
October 26, 2026 · Based on reporting by finanzen.net

Interim phase 3 results showed darolutamide cut metastasis-or-death risk by 58%, while approval for early-stage use remains outstanding.

Key takeaways

  • Darolutamide reduced the risk of metastasis or death by 58% versus placebo in the study.
  • After four years, 95% of treated patients were metastasis-free, compared with 88% in the placebo group.

Bayer shares rose after the company reported positive interim results for Nubeqa in early prostate cancer. In a phase 3 study, darolutamide combined with standard therapy reduced the risk of metastasis or death by 58% versus placebo in patients at high risk of relapse.

After four years, 95% of patients receiving the drug were metastasis-free, compared with 88% in the placebo group. Nubeqa is approved for more advanced prostate cancer, but approval for the early treatment stage studied has not yet been granted.

Bayer shares rose about 3% shortly after Monday’s market open, according to the report. As of 08:57 UTC on Monday, the stock traded at €45.16, up 2.68% from the previous close.

Topics
BAYNNubeqaDarolutamide
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.